Febuxostat 80 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).
Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).
Febuxostat 120 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).
Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether cotrimoxazole changes other adverse events clinical criteria compared with fluoroquinolones (norfloxacin) (very low certainty).
Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening probably leads to lower readmission for phototherapy for hyperbilirubinemia compared with visual assessment (moderate certainty).
Summary of findings table ‐ Transcutaneous bilirubin (TcB) screening showed no clear difference in exchange transfusion compared with visual assessment (low certainty).